Relationship between antidepressant medication possession and treatment response.

Fortney JC, Pyne JM, Edlund MJ, Mittal D. Relationship between antidepressant medication possession and treatment response. General hospital psychiatry. 2010 Jul 1; 32(4):377-9.

Related HSR&D Project(s)

• IIR 00-078 – Telemedicine Intervention to Improve Depression Care in Rural CBOCs

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

OBJECTIVE: To estimate the correlation between antidepressant medication possession ratios (MPR) measured from administrative pharmacy data and changes in self-reported depression symptoms. METHODS: The sample includes 360 primary care patients enrolled in a randomized trial of collaborative care in the Department of Veterans Affairs. Treatment response at 6 months was defined as a 50% improvement in symptoms as measured by the Hopkins Symptom Checklist (SCL-20). MPRs were calculated from administrative pharmacy data. Logistic regression analysis (controlling for intervention status and casemix) was used to test the hypothesis that MPR was significantly associated with treatment response. RESULTS: Seventy percent of the patients filled an antidepressant prescription and the average MPR was 0.46. A fifth (19.2%) of the patients responded to treatment. Having an MPR > or = 0.9 was significantly correlated with treatment response (OR = 2.43, CI(95) = 1.29-4.57, P = .006). CONCLUSIONS: If the predictive validity of antidepressant MPR measured from administrative pharmacy data is validated in other patient populations, it could be used to estimate treatment response rates whenever it is not feasible to collect symptom data directly from patients. Thus, the effectiveness of quality improvement programs designed to increase rates of antidepressant initiation and adherence could potentially be evaluated routinely at the population or system level.